The antibody-mediated rejection market consists of various monoclonal and polyclonal antibodies used for diagnosis and treatment of antibody-mediated rejection in organ transplant recipients. Antibody-mediated rejection occurs when antibodies are produced against donor organ resulting in transplant dysfunction or failure. The growing number of renal transplantations along with limited availability of donor organs is driving the demand for better diagnostics and therapeutics to prevent rejection.

The global Antibody-mediated Rejection market is estimated to be valued at US$ 126.5 Mn in 2024 and is expected to exhibit a CAGR of 12. % over the forecast period 2024-2031.

Key Takeaways

Key players operating in the antibody-mediated rejection market are CSL Behring, Hansa Biopharma AB, Viela Bio, Janssen Biotech, Pfizer. CSL Behring offers IvIg for therapy of antibody-mediated rejection of solid organs like kidneys. Hansa Biopharma's lead product imlifidase works by cleaving immunoglobulin G molecules and preventing antibodies from binding to organs. Viela Bio focuses on developing oral monoclonal antibodies to prevent transplant rejection.

The key opportunities in the antibody-mediated rejection market include development of novel drugs with longer duration of action and targeted mechanism of action to prevent rejection. Currently, most of the therapeutics are intravenous immunoglobulins requiring frequent hospital visits posing compliance issues. Oral therapies with better patient adherence can drive future growth.

Globally, the demand for organ transplantation is growing due to increasing prevalence of end-stage organ diseases. However, the limited availability of donor organs prompts the need for effective anti-rejection drugs. Major players are focusing on expanding in emerging markets of Asia Pacific, Latin America, and Middle East & Africa through additional clinical trials and partnerships with local players.

Market drivers
The increasing renal transplantations globally due to rising cases of chronic renal diseases is a major market driver. As per data, over 100,000 renal transplants are performed annually worldwide currently. Better diagnostics and anti-rejection therapies can improve allograft survival rate post transplantation boosting demand. Another key driver is limited availability of matching organs leading to the need for more effective management of antibody-mediated rejection using novel therapeutics.

Market restraints
High cost of transplantation procedures and long-term immunosuppressant therapy pose affordability issues in developing regions, restraining market growth. Many patients in these regions cannot afford the cost of anti-rejection drugs restricting adoption. Stringent regulatory approval process for new therapeutics is another challenge before biopharmaceutical players in this space.


Segment Analysis

The global antibody-mediated rejection market is dominated by the IV therapies segment. IV therapies directly infuse antibody-targeting drug therapies into patients' bloodstream through infusion. They are more direct and allow for immediate drug delivery to tissues and organs. This makes IV antibody therapies highly effective at suppressing antibody production and reducing organ rejection. Some key antibody drugs administered via IV routes are eculizumab (Soliris), alemtuzumab (Lemtrada), rituximab (Rituxan), and others. Their widespread adoption and ability to promptly deliver medication post-transplant makes IV therapies the leading segment in the antibody-mediated rejection market.

Global Analysis

Regionally, North America is expected to continue dominating the global antibody-mediated rejection market during the forecast period. The region holds majority market share currently due to developed infrastructure, high rate of organ transplantation, and presence of key players. Europe and Asia Pacific regions are expected to witness fastest growth due to increasing healthcare spending, rising healthcare awareness, and growing preference for organ transplantation in countries like China, India, and Japan. The antibody-mediated rejection drugs market is also expanding in other regions such as Latin America and Middle East & Africa due to growing medical tourism industry and improving access to advanced therapies.

Get more insights on this topic : https://justpaste.it/1r4go

What Are The Key Data Covered In This Antibody-mediated Rejection  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Antibody-mediated Rejection 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Antibody-mediated Rejection  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Antibody-mediated Rejection  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Antibody-mediated Rejection  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it